Biohaven BHV-1530 data selected for oral presentation
Biohaven said clinical data on BHV-1530, a novel FGFR3-directed ADC with a proprietary TopoIx payload, was selected for oral presentation at the EORTC-NCI-AACR Symposium 2026.
Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
1 result loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Biohaven said clinical data on BHV-1530, a novel FGFR3-directed ADC with a proprietary TopoIx payload, was selected for oral presentation at the EORTC-NCI-AACR Symposium 2026.